Exploiting Cancer Dormancy Signaling Mechanisms in Epithelial Ovarian Cancer Through Spheroid and Organoid Analysis
Cells · 2025
DOI: 10.3390/cells14020133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Emily J Tomas und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Mary and John Knight Translational Ovarian Cancer Research Unit, Verspeeten Family Cancer Centre, London, ON N6A 5W9, Canada. Hauptthemen laut MEDLINE: Spheroids, Cellular, Organoids, Carcinoma, Ovarian Epithelial, Signal Transduction. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes for Health Research, London Health Sciences Foundation through donations, the Karen Pooley Scholarship in Ovarian Cancer Research with funds from the London Health Sciences Foundation.
Abstract (Originalsprache)
Epithelial ovarian cancer (EOC) exhibits a unique mode of metastasis, involving spheroid formation in the peritoneum. Our research on EOC spheroid cell biology has provided valuable insights into the signaling plasticity associated with metastasis. We speculate that EOC cells modify their biology between tumour and spheroid states during cancer dormancy, although the specific mechanisms underlying this transition remain unknown. Here, we present novel findings from direct comparisons between cultured EOC spheroids and organoids. Our results indicated that AMP-activated protein kinase (AMPK) activity was significantly upregulated and protein kinase B (Akt) was downregulated in EOC spheroids compared to organoids, suggesting a clear differential phenotype. Through RNA sequencing analysis, we further supported these phenotypic differences and highlighted the significance of cell cycle regulation in organoids. By inhibiting the G2/M checkpoint via kinase inhibitors, we confirmed that this pathway is essential for organoids. Interestingly, our results suggest that specifically targeting aurora kinase A (AURKA) may represent a promising therapeutic strategy since our cells were equally sensitive to Alisertib treatment as both spheroids and organoids. Our findings emphasize the importance of studying cellular adaptations of EOC cells, as there may be different therapeutic targets depending on the step of EOC disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Mary and John Knight Translational Ovarian Cancer Research Unit, Verspeeten Family Cancer Centre, London, ON N6A 5W9, Canada.
- Department of Anatomy & Cell Biology, Western University, London, ON N6A 5C1, Canada.
- Department of Oncology, Western University, London, ON N6A 5C1, Canada.
- Department of Biochemistry, Western University, London, ON N6A 5C1, Canada.
- Department of Obstetrics & Gynaecology, Western University, London, ON N6A 5C1, Canada.
ORCID-Profile: Bart Kolendowski, Gabriel E DiMattia, Trevor G Shepherd
Förderung
- Canadian Institutes for Health Research
- London Health Sciences Foundation through donations
- the Karen Pooley Scholarship in Ovarian Cancer Research with funds from the London Health Sciences Foundation
Zitieren
APA
Tomas, E. J., Valdes, Y. R., Davis, J., Kolendowski, B., Buensuceso, A., DiMattia, G. E., & Shepherd, T. G. (2025). Exploiting Cancer Dormancy Signaling Mechanisms in Epithelial Ovarian Cancer Through Spheroid and Organoid Analysis. Cells. https://doi.org/10.3390/cells14020133
Vancouver
Tomas EJ, Valdes YR, Davis J, Kolendowski B, Buensuceso A, DiMattia GE, et al. Exploiting Cancer Dormancy Signaling Mechanisms in Epithelial Ovarian Cancer Through Spheroid and Organoid Analysis. Cells. 2025. doi:10.3390/cells14020133
BibTeX
@article{Tomas2025,
author = {Tomas, Emily J and Valdes, Yudith Ramos and Davis, Jennifer and Kolendowski, Bart and Buensuceso, Adrian and DiMattia, Gabriel E and Shepherd, Trevor G},
title = {Exploiting Cancer Dormancy Signaling Mechanisms in Epithelial Ovarian Cancer Through Spheroid and Organoid Analysis},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14020133}
}
EUVIMED